Avelumab and Merkel Cell Carcinoma: A Clinical Evidence Review

From General Health Science to Targeted Clinical Inquiry

The legacy of general health and science information dissemination has long provided a foundation for public understanding of disease prevention and treatment. Within this broad context, the focus on cancer biology and therapeutic interventions has evolved to address increasingly specific clinical questions. One such area involves the evaluation of immunotherapeutic agents, where the transition from general health awareness to targeted clinical scrutiny is essential. In the domain of mass production, particularly in pharmaceutical manufacturing and healthcare settings, occupational exposure to biological and chemical agents is a recognized concern. This concern extends to the handling of monoclonal antibodies, such as Avelumab, which is used in the treatment of Merkel cell carcinoma. The clinical evidence review of Avelumab’s role in Merkel cell carcinoma causation necessitates a careful pivot from general health education to the specific risks associated with occupational exposure. This shift requires an examination of how exposure to such therapeutic agents in production environments may relate to disease risk, without delving into mechanistic claims. The transition thus moves from a broad heritage of health information to a focused inquiry on the potential implications of Avelumab exposure in occupational settings, setting the stage for a rigorous review of clinical evidence.

Avelumab: Pharmacology and Clinical Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Despite these advances, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Clinical Presentation and Diagnosis of Merkel Cell Carcinoma

MCC is a rare, highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Clinical presentation typically involves a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, often in older or immunocompromised individuals. Diagnosis is confirmed by histopathology and immunohistochemistry, showing neuroendocrine markers such as cytokeratin 20 and chromogranin A. Given its aggressive nature, early detection and treatment are critical.

Avelumab Pharmacology and Reported Adverse Effects

Avelumab functions by blocking PD-L1, thereby enhancing T-cell-mediated antitumor immune responses (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; the hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case highlights the potential for avelumab to trigger or exacerbate underlying autoimmune or granulomatous conditions.

Mechanistic Pathways Linking Avelumab to Merkel Cell Carcinoma

The primary link between avelumab and MCC is therapeutic: avelumab is used to treat MCC by inhibiting PD-L1, thereby restoring immune surveillance against tumor cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, a subset of patients becomes refractory to avelumab, meaning the tumor progresses despite treatment. In such cases, alternative immune checkpoint inhibitor combinations, such as ipilimumab plus nivolumab, have shown activity in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). For example, in a multicenter study, three out of five patients with avelumab-refractory MCC responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study noted that response rates to PD-1/PD-L1 inhibition in metastatic MCC can be up to 62%, but resistance remains a significant clinical challenge (https://pubmed.ncbi.nlm.nih.gov/36450381/).

Adequacy of Warnings and Causation Considerations

Current warnings for avelumab appropriately describe its indication for metastatic MCC and the risk of immune-related adverse events, including potential reactivation of sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, the evidence does not indicate that avelumab causes MCC; rather, it is a treatment for the disease. The risk of progression or lack of response is documented, with about 50% of patients not responding to initial immune checkpoint inhibitor therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Warnings should continue to emphasize that avelumab is not curative for all patients and that refractory disease may require alternative treatment strategies. For patients who experience progression of MCC while on avelumab, causation is complex. The natural history of MCC is aggressive, and progression may reflect inherent tumor biology rather than a drug-induced effect. However, in rare cases, avelumab may trigger immune-related adverse events that complicate management, such as sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). Patients should be monitored for signs of irAEs and for disease progression. The evidence does not support a causal role for avelumab in inducing new MCC; instead, it is used to treat existing disease. The timeline between avelumab exposure and harm varies. In the case of sarcoidosis reactivation, hypercalcemia developed during treatment and resolved with corticosteroids, allowing continuation of avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who become refractory, progression may occur within weeks to months of starting therapy, as seen in clinical trials where about 50% of patients did not achieve durable responses (https://pubmed.ncbi.nlm.nih.gov/35877101/). The JAVELIN Merkel 200 trial reported objective responses in approximately one-third of patients, indicating that a majority either did not respond or progressed over time (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma (MCC), not a cause. It works by blocking PD-L1 to enhance immune response against tumor cells. The evidence does not support a causal role for avelumab in inducing new MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the risks of avelumab therapy for MCC?

Avelumab can cause immune-related adverse events (irAEs), such as reactivation of sarcoidosis leading to hypercalcemia (https://pubmed.ncbi.nlm.nih.gov/31543781/). Additionally, about 50% of patients may not respond or may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

What is the timeline for harm from avelumab exposure?

Harm can occur within weeks to months. For example, hypercalcemia from sarcoidosis reactivation developed during treatment (https://pubmed.ncbi.nlm.nih.gov/31543781/). Progression of MCC may also occur within weeks to months of starting therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.